Xaira Therapeutics at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Xaira Therapeutics at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Xaira Therapeutics South San Francisco, California	1 Associate Scientist
xaira.com\|LinkedIn AI drug discovery company developing predictive models, biological datasets, and therapeutics for patients. Appointed Ian McCaffery as SVP of translational science and early clinical development, building out its drug-development leadership. › Appointed Ian McCaffery as SVP of translational science and early clinical development, building out its drug-development leadership. 2026-07 · source Appointed Rachel Lane to lead business development and operations, a leadership hire as it builds out partnering functions. 2026-03 · source Launched X-Cell, a virtual cell model trained on its largest-ever genome-wide perturbation dataset, a major new AI drug-discovery tool. 2026-03 · source Source: company newsroom Raised nearly $1 billion (Mar 2026) › Lead investors were not named in the company's own announcement. · 2026-03-23 “Xaira Therapeutics raised nearly $1 billion.” Source: funding announcement	Poster Fri Oct 23 2:30 pm Part of Artificial Intelligence and Machine Learning Poster Friday Session X-Cell: A High-Capacity Generative Framework for Systematic, In Silico Mapping of Causal Gene Functions Exhibit & Poster Hall · Board 8110F Artificial intelligenceGenome editing/CRISPRGenomicsPrecision medicine

Organization

ASHG 2026 Attendance

South San Francisco, California

1 Associate Scientist

AI drug discovery company developing predictive models, biological datasets, and therapeutics for patients.

Appointed Ian McCaffery as SVP of translational science and early clinical development, building out its drug-development leadership.

›

Appointed Ian McCaffery as SVP of translational science and early clinical development, building out its drug-development leadership.

2026-07 · source

Appointed Rachel Lane to lead business development and operations, a leadership hire as it builds out partnering functions.

2026-03 · source

Launched X-Cell, a virtual cell model trained on its largest-ever genome-wide perturbation dataset, a major new AI drug-discovery tool.

2026-03 · source

Raised nearly $1 billion (Mar 2026)

›

Lead investors were not named in the company's own announcement. · 2026-03-23

“Xaira Therapeutics raised nearly $1 billion.”

Poster

Fri Oct 23
2:30 pm

Artificial intelligenceGenome editing/CRISPRGenomicsPrecision medicine

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction